Raymond James reiterated coverage on G1 Therapeutics with a new price target
$GTHX
Biotechnology: Pharmaceutical Preparations
Health Care
Raymond James reiterated coverage of G1 Therapeutics with a rating of Outperform and set a new price target of $24.00 from $41.00 previously